Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across…
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Qynapse‘s QyScore, a software that aids in analyzing brain scans taken by magnetic resonance imaging (MRI). The software, which is compatible with routine imaging workflows, includes an advanced user interface and automatically-generated patient reports.
The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…
A new small molecule called synucleozid can prevent cells from producing the Parkinson’s-associated protein alpha-synuclein by inhibiting its translation from RNA, a study shows. The study, “Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA,” was published in…
People with Parkinson’s disease taking part in the Fox Insight study, where they self-report details about their illness, share similar clinical and demographic features with patients brought through more traditional ways into large data studies, researchers report. This finding suggests that groups recruited exclusively online can be useful to Parkinson’s…
Stimulating the growth of blood vessels in the brain through the use of fibroblast growth factor 1 (FGF1) may hold promise as a strategy for treating Parkinson’s disease, according to a white paper released by Zhittya Genesis Medicine (ZGM). Clinical trials testing this theory are being planned.
A decade after its founding, the International Parkinson Disease Genomics Consortium (IPDGC) is looking back on on its first 10 years of research and outlining its goals for the future. IPDGC was started in 2009 by a small group of researchers who thought that collaborative efforts were necessary to…
A compound that affects some of the same receptors in the brain as cannabis could help reduce dyskinesia — involuntary muscle movement — that develops following levodopa treatment in Parkinson’s disease, a new study done in mice suggests. The mice were treated with HU-308, an…
In Parkinson’s patients, the risk of falls increases depending on disease duration and having the postural instability/gait disturbance (PIDG) subtype, but is not signficantly correlated with non-motor symptoms, a study suggests. The study, titled “Falls in persons with Parkinson’s disease: Do non-motor symptoms matter as much…
Interactive sessions, including games that are intended to help elderly Parkinson’s patients learn strategies to avoid falling, are well-received, a small Brazilian study suggests. The study, “Gerontotechnology for fall prevention of the elderly with Parkinson,” was published recently in Revista Brasileira de Enfermagem. Falling is a major…
Get regular updates to your inbox.